Drug Profile
Brinzolamide
Alternative Names: AL 4862; Azopt; Azopt ophthalmic suspensionLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Alcon
- Developer Novartis
- Class Antiglaucomas; Sulfonamides; Thiazines
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Glaucoma; Ocular hypertension
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon eye care devices business
- 08 Apr 2011 Novartis completes acquisition of Alcon
- 26 Aug 2010 Alcon has been acquired by Novartis